Recruiting NCT07279714
Fisetin in Mild Alzheimer's Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Fisetin.
- Who it may be relevant to
- Registry conditions: Alzheimer s Disease, Alzheimer Dementia, Alzheimer Dementia (AD), Alzheimer Disease. Basic parameters: from 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Fisetin Intervention Study in Mild Alzheimer's Disease
Overview
This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.
Interventions
- Other Fisetin
Fisetin 20mg/kg/day
Primary outcome measures
- Incidence of Treatment-Emergent Adverse Events (Safety and tolerability of fisetin) [Time frame: 30 days]
Eligibility criteria
Inclusion criteria
- Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia
- Moca score of 11 or higher
- Stable psychotropics and cognitive enhancing medications
Exclusion criteria
- Known hypersensitivity or allergy to fisetin
- Presence of any medical condition, or abnormal routine blood test, that the investigator believes would put the subject at risk or would preclude the patient from completing all aspects of the trial
- Unstable medical disorders
- Ongoing treatment for active infection with antibiotics/antifungals
- Ongoing treatment for cancer
- Active alcohol or substance use disorder
- Recent active bleeding
- Patients taking oral anticoagulants, anti-cancer, anti-seizure medications, or other medications that could have a significant interaction with fisetin
- Use within the last month of other senolytic supplements, antioxidant supplements, natural health products
- Other neurologic or neurodegenerative conditions impacting cognition
- Active Major Depressive Episode, active suicidal thoughts or psychosis
- Any thing that would preclude the ability to undergo an MRI scan
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Canada · 1 center
- Sunnybrook Research Institute — Toronto
Identifiers
NCT: NCT07279714 · 6705